Search our science

Search our scientific publications and resources
on rare bleeding disorders

Molecule
Study Phase
Content Type


Scientific resources from Novo Nordisk

Novo Nordisk supports sharing of the scientific research on our molecules. The search results below include peer-reviewed articles that are authored by Novo Nordisk employees or are funded by Novo Nordisk, as well as congress abstracts, posters and presentations, and also related educational resources.

 

Search Results

We found 383 resources matching your search criteria

Poster
Matino D, Iorio A, Keepanasseril A, Germini F, Birkegård AC, Caillaud A, Carcao M, Hews-Girard J, Iserman E, James P, Lee A, Phua C, Sun H, Teitel J, Poon M-. A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1)
Abstract
Giangrande P, Lee XY, Curry N, Benchikh El Fegoun S. Prophylaxis with Turoctocog Alfa Pegol (N8-GP) Maintains Improvements in Health-Related Quality of Life (HRQoL) and Treatment Satisfaction (TS) over ?4.5 Years in Patients with Haemophilia A (HA) [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1).
Abstract
Matino D, Iorio A, Keepanasseril A, Germini F, Birkegård AC, Caillaud A, Carcao M, Hews-Girard J, Iserman E, James P, Lee A, Phua C, Sun H, Teitel J, Poon M-. A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1)
Abstract
Lund J, Østergaard H, Greisen PJ, Bonde AC, Gandhi PS, Lorenzen N, Johansson E, Andersen LM, Rasch MG, Lund S, Zhou R, Bjelke JR, Røder G, Johnsen LB, Stavenuiter F, Egebjerg T, Henriksen A, Hansen BG, Thorn K, Hilden I. A Novel FVIIIa-Mimetic Bispecific Antibody, Mim8, Enhances FIXa Proteolytic Activity While Allowing for Efficient, Lipid-Dependent Assembly with FX [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1)
Primary manuscript
Wu R, Sun J, Xu W, Hu Q, Li W, Xiao J, Yang F, Zeng X, Zeng Y, Zhou J, Matytsina I, Zhang S, Pluta M, Yang R. Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial. Ther Clin Risk Manag. 2020;16:567-578
Animated publication summary

Wu R, Sun J, Xu W, Hu Q, Li W, Xiao J, Yang F, Zeng X, Zeng Y, Zhou J, Matytsina I, Zhang S, Pluta M, Yang R. Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial. Ther Clin Risk Manag. 2020;16:567-578

Primary manuscript
Wu R, Sun J, Xu W, Hu Q, Li W, Xiao J, Yang F, Zeng X, Zeng Y, Zhou J, Matytsina I, Zhang S, Pluta M, Yang R. Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial. Ther Clin Risk Manag. 2020;16:567-578
Primary manuscript
Wang M, Peltier S, Baumann K, Sidonio R, Witkop M, Cooper D, Waters E, Kahan S, Croteau S, Cutter S, Hernandez G, Wicklund B, Dreyer Gillette M, Haugstad K, Ostrow V, Nadglowski J. ACTION-TO-HOPE HCP and Consumer Results Supplement. Haemophilia. 2020;26(S1):3-19.

This website is intended
for healthcare professionals (HCPs)
outside of the U.S.

Take me to www.novonordisk.com